Exploring adjuvant therapies for hepatocellular carcinoma post curative treatment and the unanswered questions they raise in patient management.
- Hepatocellular carcinoma (HCC) is a common malignancy with high recurrence rates after curative treatments like hepatectomy or ablation.
- Adjuvant therapies, including antiviral therapy, transarterial chemoembolization (TACE), and immune checkpoint inhibitors (ICIs), are being explored to reduce recurrence rates and improve patient outcomes.
- Risk factors for HCC recurrence differ between early and late recurrence, guiding the choice of adjuvant therapy based on specific patient profiles.
- ICIs, in particular, have shown promise in reducing recurrence rates and improving survival outcomes in HCC patients.
- Ongoing research and international collaboration are crucial to establish standardized treatment protocols and enhance the prognosis for HCC patients worldwide.
Source link
Oncology, Gastroenterology, Surgery